Search

POSTDOCTORAL FELLOWSHIP IN DECISION MODELING AND CANCER SURVIVORSHIP The Division of General Pediatrics at Boston Children’s Hospital is seeking a highly motivated and capable decision scientist, epidemiologist or outcomes researcher with an interest in cancer prevention and survivorship. The fellow...

Harvard/MIT Equitable Access to Research Training (HEART) MD-PhD Summer Program The HEART MD-PhD Summer Program is a specialty track within SHURP focused on students interested in MD-PhD training, founded by current students in Harvard's MD-PhD program. Mission Statement: The HEART MD-PhD Summer...

DOWNLOAD FULL ISSUE Inclusion, Diversity, and Equity at Harvard Ophthalmology In the latest issue of Eye Witness, we highlight our latest efforts on inclusion, diversity, and equity, including our EYE CAN program, a multi-tiered framework created by our IDE leaders that aims to increase diversity...

Date Speaker Monday, December 5, 2022 Christopher Burd, MS, PhD. (Yale, CT) Host: Wayne Lencer, MD. Monday, January 9, 2023 Nicholas Zachos, PhD. (Nashville, TN) Host: Jerrold Turner, MD, PhD. Monday, March 6, 2023 Marcia B. Goldberg, MD. (MGH, HMS) Host: Wayne Lencer, MD. Monday, April 3, 2023 Ruth...

Tuesday, May 23, 2023 - More info will be posted soon

Dear Colleagues, In this issue of eye Insights, we take a close look at posterior uveitis. Inside, you’ll find techniques and tips for evaluating and managing patients with this condition. Due to its many etiologies, posterior uveitis can be challenging to treat until the cause of the inflammation...

The most common symptoms of posterior uveitis are blurred vision and floaters, and the most common signs are chorioretinal infiltrates and vitreous cells. Posterior uveitis is diagnosed by slit lamp examination and indirect ophthalmoscopy. Imaging modalities, including fundus autofluorescence...

While gene therapy is not yet widely available for inherited retinal disorsers (IRDs), researchers are making exciting discoveries, and the future looks more promising than ever before. In this issue of eye Insights, we provide a look into current offerings in gene therapy, and a glimpse into the...

Inherited retinal disorders are rare, hereditary disorders caused by mutations in genes that encode proteins needed for normal retinal health and function. The first gene associated with retinitis pigmentosa was identified at Mass Eye and Ear in 1990, and since then, over 250 IRD-causing genes have...

The first gene-augmentation therapy for an IRD was approved by the U.S. Food and Drug Administration (FDA) in December 2017 after nearly two decades of development in preclinical models and clinical trials. The drug, known as Luxturna®, is for individuals with autosomal recessive retinal dystrophies...